A new, large-scale clinical trial named ASPIRE is underway to test whether a combined approach of chemotherapy and next-generation therapies could further improve the lives of men with advanced prostate cancer. The ASPIRE trial stands out in both its size and its commitment to personalizing prostate cancer care through genetic analysis.

Note: do not mistake this ASPIRE trial for the ASpiRE trial we talked about here.

The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial , a Phase III multicenter study designed to enroll 1,200 patients with metastatic castrate-sensitive prostate cancer (mCSPC) from across the United States. The central question: does adding docetaxel, a well-established chemotherapy agent, to standard treatment regimens extend survival for newly diagnosed men with mCSPC? Participants in the ASPIRE study are randomized to one of two treatment groups:

Standard arm: Hormone therapy combined with apalutamide, a next-generation androgen receptor inhibitor.

Intervention arm: Hormone therapy plus apalutamide, with the addition of intravenous docetaxel administered every 21 days, for up to six cycles.

The primary goal is to determine if early treatment intensification improves overall survival. Researchers will also analyze progression-free survival and quality of life as important secondary endpoints.

One of the innovative aspects of the ASPIRE trial is its incorporation of genetic profiling. The team will examine if patients with mutations in TP53, PTEN, or RB1, genomic markers linked to more aggressive prostate cancer, gain greater benefit from the intensification strategy. This focus represents a growing movement toward precision oncology, where the molecular features of each patient’s cancer can influence treatment decisions.

Supported by the National Cancer Institute (NCI) and the National Clinical Trials Network, the ASPIRE trial has potential to reshape standards for advanced prostate cancer treatment.

Source.